Diabetes News

A risk model accurately categorized patients with an inpatient episode of acute kidney injury into clinically distinct groups according to likelihood of either death or recovery of kidney function and ability to discontinue dialysis after hospital discharge, according to a published study.

Prevalence of nonalcoholic fatty liver disease — and its more severe stage, nonalcoholic steatohepatitis, or NASH, in particular — is increasing in developed countries. The condition has surpassed alcoholism as a cause of cirrhosis and will soon be the primary cause of liver transplantation in the United States, exceeding hepatitis C, according to Kenneth Cusi, MD, FACP, FACE, chief of the division of endocrinology, diabetes and metabolism at University of Florida.

Examining small-molecule metabolites in the blood may serve as an effective alternative to kidney biopsy for the identification of diabetic kidney disease in patients with type 2 diabetes, according to research presented at the American Physiological Society/American Society of Nephrology conference.

BOSTON — Female kidney transplant recipients who conceived between the ages of 18 and 25 years had higher rates of rejection and graft loss, as well as higher serum creatinine post-pregnancy, than women who were older at the age of conception, according to a speaker at the American Transplant Congress.

The rate of diabetes screening in the U.S. rose from 2012 to 2015 but still remained below 15%, according to findings recently published in the Journal of the American Board of Family Medicine.

BOSTON — For transplant recipients with type 2 diabetes, delayed graft function was more common in those with higher BMIs and allograft survival was lowest in those categorized as obese or underweight, according to research presented at the American Transplant Congress.

SAN FRANCISCO — A 1.5 mg daily dose of dulaglutide may limit kidney function deterioration and the onset of end-stage renal disease for adults with type 2 diabetes and chronic kidney disease, particularly when macroalbuminuria is also present, according to findings presented at the American Diabetes Association Scientific Sessions.

SAN FRANCISCO —Beyond improved cardiovascular outcomes, the SGLT2 inhibitor dapagliflozin may also offer adults with type 2 diabetes the potential to prevent and treat kidney disease, according to findings presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet Diabetes & Endocrinology.

SAN FRANCISCO — In adults with type 2 diabetes, established cardiovascular disease and renal impairment, the DPP-IV inhibitor linagliptin did not increase risk for a new CV event or progression of renal disease when compared with placebo, regardless of age or the level of renal impairment, according to new findings from the CARMELINA trial presented at the American Diabetes Association Scientific Sessions.

SAN FRANCISCO — In a large cohort of adults with type 2 diabetes with and without established cardiovascular disease, the once-weekly GLP-1 receptor agonist dulaglutide reduced the risk for nonfatal myocardial infarction, nonfatal stroke and CV death by 12% compared with placebo, according to data from the REWIND study presented at the American Diabetes Association Scientific Sessions.